INKT:NASDAQMiNK Therapeutics, Inc. Analysis

MiNK Therapeutics (INKT) trades at $12.33, well below its analyst median target of $39, implying a potential upside of over 200%. The stock sits just above its 20‑day SMA ($11.78) and 50‑day SMA ($11.65) while remaining under the 200‑day SMA ($12.20), suggesting a short‑term bounce but a longer‑term neutral bias. Technical momentum is modestly bullish with a MACD histogram of +0.03 and an RSI of 55, indicating neither overbought nor oversold conditions. Volume is on a decreasing trend and daily volume is thin (~6.6k shares), flagging liquidity concerns. Fundamentally, the company reports zero revenue, negative EBITDA of $‑12.8M, and a forward PE of –4.3, reflecting heavy development-stage losses. The beta of –1.19 points to an inverse correlation with the market, while 30‑day volatility is extremely high at 79%, and the historical max drawdown exceeds 86%, underscoring substantial price swings. The Fear & Greed Index reads “Extreme Greed” (91.36), hinting at bullish market sentiment despite the risk profile. Upcoming catalysts include the Q1‑2026 financial release (May 8) and the virtual 2026 Annual Shareholders Meeting (June 3), which could provide updates on the Phase 2 agenT‑797 trial and other iNKT programs.